JPMorgan Chase & Co. lessened its holdings in Enhabit, Inc. (NYSE:EHAB - Free Report) by 74.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 78,574 shares of the company's stock after selling 226,671 shares during the quarter. JPMorgan Chase & Co. owned about 0.16% of Enhabit worth $614,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Quantbot Technologies LP bought a new position in Enhabit in the 4th quarter worth about $45,000. Corient Private Wealth LLC purchased a new stake in shares of Enhabit in the fourth quarter valued at approximately $79,000. Stoneridge Investment Partners LLC raised its holdings in Enhabit by 22.6% in the 4th quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company's stock valued at $98,000 after buying an additional 2,308 shares during the period. Intech Investment Management LLC raised its holdings in shares of Enhabit by 27.6% in the 4th quarter. Intech Investment Management LLC now owns 15,481 shares of the company's stock valued at $121,000 after buying an additional 3,353 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Enhabit during the fourth quarter worth $124,000.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group reiterated a "buy" rating on shares of Enhabit in a research report on Thursday, March 6th.
Check Out Our Latest Stock Report on Enhabit
Enhabit Stock Performance
EHAB traded up $0.17 on Friday, hitting $8.02. 414,965 shares of the company traded hands, compared to its average volume of 481,085. The stock has a market capitalization of $404.85 million, a PE ratio of -3.46 and a beta of 1.60. The company has a 50 day moving average of $8.28 and a 200-day moving average of $8.02. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. Enhabit, Inc. has a 12-month low of $6.85 and a 12-month high of $10.70.
About Enhabit
(
Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Featured Stories
Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
